Review
Pharmacology & Pharmacy
Yinghui Wang, Lu Gao
Summary: Chronic kidney disease and cardiac insufficiency often co-exist, especially in uremic patients on hemodialysis. Impaired renal function is often indicative of poor prognosis in patients with cardiac insufficiency. Inflammation plays a significant role in the development of cardiovascular complications in patients with chronic kidney disease and is indicative of prognosis.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Ethan S. Rosenfeld, Gregory D. Trachiotis, Andrew D. Sparks, Michael A. Napolitano, K. Benjamin Lee, Daniel Wendt, Teresa M. Kieser, John D. Puskas, Gabriele DiGiammarco, David P. Taggart
Summary: Patients with chronic and ESRD undergoing CABG procedures with high-frequency ultrasound and TTFM experience more surgical strategy changes than patients with normal renal function while achieving comparable graft flow parameters post-protamine.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
(2021)
Review
Cardiac & Cardiovascular Systems
Daniel Hirsch, Brandon Lau, Virag Kushwaha, Kenneth Yong
Summary: Cardiovascular disease (CVD) is the leading cause of death among end-stage kidney disease (ESKD) patients, with a significant proportion of cases attributed to coronary artery disease (CAD) due to atherosclerosis. However, other CVD pathologies including myocardial fibrosis, vascular calcification, and arterial stiffening also contribute to the risk. The pathophysiology and treatment of CAD in ESKD patients differ from the general population, with diffuse multi-vessel involvement and increased calcification. Modulating inflammation may be a potential therapeutic target for improving CVD outcomes in ESKD patients. The optimal strategy for screening and managing stable CAD in ESKD patients is still being investigated.
REVIEWS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Zixiang Ye, Yaxin Wu, Yimin Tu, Mulei Chen, Yanxiang Gao, Linying Shi, Peizhao Li, Enmin Xie, Ziyu Guo, Qing Li, Xiaozhai Yu, Yike Li, Wenquan Niu, Jingyi Ren, Jingang Zheng
Summary: This study demonstrates that blood group O may be negatively associated with the risk and severity of coronary artery disease (CAD) in end-stage renal disease (ESRD) patients undergoing dialysis, while blood groups A, B, and AB may be positively associated with the severity of CAD.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Evgenii Gusev, Liliya Solomatina, Yulia Zhuravleva, Alexey Sarapultsev
Summary: Chronic kidney disease can progress to end-stage chronic renal disease, requiring replacement therapy. ESRD leads to irreversible kidney changes associated with systemic inflammatory changes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Kuo-Hua Lee, Yuan-Chia Chu, Ming-Tsun Tsai, Wei-Cheng Tseng, Yao-Ping Lin, Shuo-Ming Ou, Der-Cherng Tarng
Summary: This study used machine learning to predict the risk of end-stage renal disease (ESRD) in sepsis survivors. The researchers found that estimated glomerular filtration rates, hemoglobin, and proteinuria were important predictors of ESRD development.
Article
Biochemistry & Molecular Biology
Ziad M. El-Zaatari, Luan D. Truong
Summary: Renal cell carcinoma (RCC) occurring in the setting of end-stage renal disease (ESRD) shows unique clinicopathological characteristics, with acquired cystic kidney disease-associated renal cell carcinoma (ACKD-RCC) and clear-cell papillary renal cell carcinoma (ccpRCC) being the most frequent types. Other types of RCC also occur in ESRD, albeit with different frequencies from the non-ESRD general population. While the histological features of RCC do not vary in the setting of ESRD vs. non-ESRD, other findings, such as multifocality and multiple tumor types, are more frequent in ESRD. Studies have generated novel and important knowledge of the etiology, epidemiology, diagnosis, treatment, immunophenotype, and molecular characteristics of ESRD-associated RCC.
Article
Multidisciplinary Sciences
Lina A. Dahabiyeh, Refat M. Nimer, Khalid M. Sumaily, Mohamad S. Alabdaljabar, Minnie Jacob, Essa M. Sabi, Maged H. Hussein, Anas Abdel Rahman
Summary: Chronic kidney disease (CKD) is a severe public health problem that can lead to end-stage renal disease (ESRD) requiring dialysis or transplantation. This study identified altered metabolites and biochemical reactions between ESRD and CKD, offering potential new biomarkers for monitoring CKD progression. Inhibition of the kynurenine pathway may be a promising target for delaying CKD progression, and metabolites with high discriminative ability could complement current markers to better indicate kidney damage status.
SCIENTIFIC REPORTS
(2023)
Article
Biochemistry & Molecular Biology
Mahmoud M. Zakaria, Safaa A. Derbala, Ayman E. Salem, Amgad E. EL-Agroudy, Fatma M. El-Tantawy
Summary: The study found that ESRD patients have a significantly lower number of T-cell subsets compared to CKD patients, which is related to a higher degree of apoptosis in these cells.
MOLECULAR BIOLOGY REPORTS
(2021)
Article
Medicine, General & Internal
Fatma M. El-Senosy, Rasha Elsayed Mohamed Abd El Aziz, Sammar Ahmed Kasim, Lamia Abdulbary Gad, Donia Ahmed Hassan, Seham Sabry, Ismail Mohamed El Mancy, Taiseer Ahmed Shawky, Ibrahim Ghounim Ramadan Mohamed, Rady Elmonier, Essam Kotb, Abeer Mohammed Abdul-Mohymen
Summary: This study assessed the relationship between serum endocan levels and subclinical atherosclerosis in patients with chronic kidney disease and on hemodialysis. The results showed that endocan levels were associated with subclinical atherosclerosis and the hyperinflammatory state in these patients.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
(2022)
Article
Immunology
Robson E. Silva, Eliziaria C. Santos, Patricia B. Justino, Margarida P. Santos, Giovane Galdino, Reggiani Goncalves, Romulo D. Novaes
Summary: The relationship between dialysis adequacy and circulating levels of inflammatory mediators was investigated, showing that low Kt/V results and creatinine accumulation may serve as potential indicators of systemic inflammatory stress.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Paul M. Ridker, Katherine R. Tuttle, Vlado Perkovic, Peter Libby, Jean G. MacFadyen
Summary: This study found that residual inflammatory risk plays a significant role in determining the risk of recurrent major adverse cardiovascular events among post-myocardial infarction patients already treated with statins, especially in those with impaired kidney function.
EUROPEAN HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Samuel Ji Quan Koh, Jonathan Yap, Yilin Jiang, Gerald Gui Ren Sng, Yi Hua Low, Yee How Lau, Yoong Kong Kenny Sin, Khung Keong Yeo
Summary: This study aimed to determine the optimal management of patients with end-stage renal disease (ESRD) on dialysis with severe coronary artery disease (CAD). The treatment modality did not impact on 1-year mortality, however, the CABG group had significantly lower 1-year MACE rates. Independent predictors of overall mortality included STEMI presentation, prior heart failure, LM disease, NSTE-ACS presentation, and increased age.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Article
Medicine, General & Internal
Xihui Li, Feng Xiao, Siyu Zhang
Summary: This study compared the outcomes of CABG and PCI in revascularizing coronary arteries in patients with CKD and ESRD. It found that patients with ESRD who underwent CABG had lower overall and cardiac mortality, but there was an increased risk of early mortality. PCI was associated with higher rates of repeat revascularization and myocardial infarction in both CKD and ESRD patients. More research is needed to determine the optimal revascularization strategy for these patients.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
(2021)
Article
Cardiac & Cardiovascular Systems
Tjerk S. J. Opstal, Aernoud T. L. Fiolet, Amber van Broekhoven, Arend Mosterd, John W. Eikelboom, Stefan M. Nidorf, Peter L. Thompson, Michiel Duyvendak, J. W. Martijn van Eck, Eugene A. van Beek, Frank den Hartog, Charley A. Budgeon, Willem A. Bax, Jan G. P. Tijssen, Saloua El Messaoudi, Jan H. Cornel
Summary: This study found that the benefits of colchicine in reducing major adverse cardiovascular events are consistent regardless of the history and timing of prior acute coronary syndrome (ACS).
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
